146 related articles for article (PubMed ID: 28408193)
1. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study.
Agger JL; Schröder A; Gormsen LK; Jensen JS; Jensen TS; Fink PK
Lancet Psychiatry; 2017 May; 4(5):378-388. PubMed ID: 28408193
[TBL] [Abstract][Full Text] [Related]
2. Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial.
Cheong PK; Ford AC; Cheung CKY; Ching JYL; Chan Y; Sung JJY; Chan FKL; Wu JCY
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):837-844. PubMed ID: 30361080
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
8. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
12. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
14. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.
Philipp M; Kohnen R; Hiller KO
BMJ; 1999 Dec; 319(7224):1534-8. PubMed ID: 10591711
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
[TBL] [Abstract][Full Text] [Related]
19. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Taha AS; McCloskey C; McSkimming P; McConnachie A
Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):469-476. PubMed ID: 29754836
[TBL] [Abstract][Full Text] [Related]
20. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]